Austeja Baleviciute
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Austeja Baleviciute has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Augustinas Želvys
Faculty of Electronics, Vilnius Gediminas Technical University, LT-10223 Vilnius, Lithuania
8 shared publications - Vitalij Novickij
Vilnius Gediminas Technical University
6 shared publications - Eivina Radzevičiūtė-Valčiukė
Department of Immunology and Bioelectrochemistry, State Research Institute Centre for Innovative Medicine, Santariškių 5, 08410 Vilnius, Lithuania
5 shared publications - Aukse Zinkeviciene
Department of Immunology and Bioelectrochemistry, State Research Institute Centre for Innovative Medicine, LT-08410 Vilnius, Lithuania
4 shared publications - Lily Keane
APC Microbiome Ireland, University College Cork, Cork, Ireland
4 shared publications - Audrius Kucinskas
Biological Research Center, Lithuanian University of Health Sciences, Tilzes Str. 18/7, LT-47181 Kaunas, Lithuania
3 shared publications
Latest Publications
- 30 September 2026
- Published by Elsevier in Seminars in Hematology
Evolution of Gene Therapy in Hematology
- 30 September 2026
- Published by Elsevier in Seminars in Hematology
Evolution of Gene Therapy in Hematology
- Open Access
- 19 August 2026
- Published by Karolinska Institutet
Microglia contribute to gliomagenesis across the lifespan : mechanisms and therapeutic interventions
High-grade gliomas remain the most devastating among primary central nervous system (CNS) tumours. Despite major advances in the molecular classification and understanding of glioma biology, these malignancies are incurable across the lifespan. In adults, glioblastoma (CNS WHO grade 4, IDH wildtype) is the most common malignant primary brain tumour. Standard treatment consists of surgical resection and radiotherapy combined with chemotherapeutics such as temozolomide, however, recurrence is inevitable. Similarly to adult glioblastoma, diffuse midline glioma (DMG) formerly known as diffuse intrinsic pontine glioma (DIPG) is one of the most aggressive paediatric CNS malignancies characterized by the alterations in the histone H3 at amino acid position 27 where commonly lysine is substituted with methionine (often referred to as K27M or K27-altered). DMG arises along critical midline structures where the location and diffuse nature of the tumour make surgical resection not possible. Available treatment options such as radiotherapy serve only as palliative care and offer only a modest survival benefit. Despite distinct developmental contexts, anatomical distributions and molecular alterations, paediatric and adult high-grade gliomas share poor clinical outcomes due to the aggressive nature of these tumours and their resistance to currently available treatment. These shared challenges encourage to look for new therapeutic opportunities, particularly considering the tumour microenvironment (TME) which provides a complex cellular and molecular context for tumour progression, immune evasion and therapeutic resistance. Therefore, understanding intrinsic and extrinsic factors that affect the glioma microenvironment is essential for the development of effective therapeutic strategies.Among the diverse glioma TME components, microglia emerge as key regulators of disease progression owing to their remarkable capacity to dynamically remodel their activation state in response to developmental, environmental and pathological cues. As the resident immune cells of the brain, microglia are responsible for regulating CNS homeostasis and immune surveillance throughout life, while also performing specialized functions such as synaptic pruning during development and maintenance of neural integrity across adulthood and ageing. In disease contexts, particularly in gliomas, microglia are far more than passive responders. Gliomas actively exploit this plasticity of microglia, reprogramming them into functional activation states that regulate extracellular matrix remodelling, angiogenesis, tumour invasion, peripheral immune cell recruitment, antigen presentation and adaptive immune responses. This dynamic microglial reprogramming is shaped throughout life by the integration of various intrinsic and extrinsic regulatory programmes. Microglial phenotype and function are shaped by the interplay between cell-intrinsic programmes, including transcriptional, epigenetic and metabolic regulation, and signals from the surrounding environment. These extrinsic influences vary across the lifespan and include cues from the local CNS environment, systemic immunity and the gut microbiome, as well as signals arising within the tumour microenvironment during glioma. Understanding how these intrinsic and extrinsic mechanisms spatiotemporally render different microglial activation states and functions has become a central challenge in the research of glioma biology, representing a promising avenue for therapeutic interventions.In line with these observations, this thesis investigates how intrinsic developmental programs and extrinsic cues shape microglia across the lifespan and influence the progression of glioma, one of the most aggressive brain tumours. In Paper I, we identified a distinct CD11c+ microglial activation state that promotes dysfunctional adaptive immune responses by chronically activating and exhausting the T cells in DMG. In Paper II, we investigated how DMG drives the remodelling of the gut microbiome which in turn is associated with the establishment of an immunosuppressive microglial niche within the tumour microenvironment. Considering bi-directional communication of the gut-brain-axis, in Paper III, we show that early-life microbiota shape developmental microglial programmes that influence susceptibility to DMG. In Paper IV, we identified the intrinsic ID2-ETS2 transcriptional axis that regulates a switch in microglia towards a pro-tumoral activation state in adult glioblastoma. Finally, in Paper V, we characterised age-associated microglial transcriptomic states that impair immunogenicity, providing insight into how ageing may contribute to the emergence and progression of adult gliomas. Collectively, these studies provide a framework for understanding how developmental, environmental and disease-associated factors shape microglial states and functions across the lifespan, offering new insights into their contribution to gliomagenesis and potential as therapeutic targets.List of scientific papersI. CD11c+ microglia promote dysfunctional T-cell activation in diffuse midline glioma. Austėja Balevičiūtė, Cristina Cuesta-Marti, Jessica Hincks, Mya McCarthy Hogan, Brendan L. Sharvin, Meghan McDermott, Jessica O'Reilly, Gabriel S.S. Tofani, Aimee du Chatinier, Gerard M. Moloney, Pat Fitzgerald, Cathriona Foley, Olivia F. O'Leary, Timothy N Phoenix, Esther Hullerman, Jon D. Larson, Suzanne J. Baker, Gerard Clarke, John F. Cryan & Lily Keane. Manuscript under revision at Immunity. [Submitted]II. Dynamic gut microbiome remodelling during diffuse midline glioma progression associates with an immunosuppressive microglial niche. Austėja Balevičiūtė*, Cristina Cuesta-Marti*, Ramya Balasubramanian*, Brendan L. Sharvin, Meghan McDermott, Jessica Hincks, Jessica O'Reilly, Aimee du Chatinier, Gerard M. Moloney, Pat Fitzgerald, Timothy N Phoenix, Esther Hullerman, Paul Cotter, Gerard...
- 19 August 2026
- Published by Karolinska Institutet
Open AccessMicroglia contribute to gliomagenesis across the lifespan : mechanisms and therapeutic interventions
High-grade gliomas remain the most devastating among primary central nervous system (CNS) tumours. Despite major advances in the molecular classification and understanding of glioma biology, these malignancies are incurable across the lifespan. In adults, glioblastoma (CNS WHO grade 4, IDH wildtype) is the most common malignant primary brain tumour. Standard treatment consists of surgical resection and radiotherapy combined with chemotherapeutics such as temozolomide, however, recurrence is inevitable. Similarly to adult glioblastoma, diffuse midline glioma (DMG) formerly known as diffuse intrinsic pontine glioma (DIPG) is one of the most aggressive paediatric CNS malignancies characterized by the alterations in the histone H3 at amino acid position 27 where commonly lysine is substituted with methionine (often referred to as K27M or K27-altered). DMG arises along critical midline structures where the location and diffuse nature of the tumour make surgical resection not possible. Available treatment options such as radiotherapy serve only as palliative care and offer only a modest survival benefit. Despite distinct developmental contexts, anatomical distributions and molecular alterations, paediatric and adult high-grade gliomas share poor clinical outcomes due to the aggressive nature of these tumours and their resistance to currently available treatment. These shared challenges encourage to look for new therapeutic opportunities, particularly considering the tumour microenvironment (TME) which provides a complex cellular and molecular context for tumour progression, immune evasion and therapeutic resistance. Therefore, understanding intrinsic and extrinsic factors that affect the glioma microenvironment is essential for the development of effective therapeutic strategies.Among the diverse glioma TME components, microglia emerge as key regulators of disease progression owing to their remarkable capacity to dynamically remodel their activation state in response to developmental, environmental and pathological cues. As the resident immune cells of the brain, microglia are responsible for regulating CNS homeostasis and immune surveillance throughout life, while also performing specialized functions such as synaptic pruning during development and maintenance of neural integrity across adulthood and ageing. In disease contexts, particularly in gliomas, microglia are far more than passive responders. Gliomas actively exploit this plasticity of microglia, reprogramming them into functional activation states that regulate extracellular matrix remodelling, angiogenesis, tumour invasion, peripheral immune cell recruitment, antigen presentation and adaptive immune responses. This dynamic microglial reprogramming is shaped throughout life by the integration of various intrinsic and extrinsic regulatory programmes. Microglial phenotype and function are shaped by the interplay between cell-intrinsic programmes, including transcriptional, epigenetic and metabolic regulation, and signals from the surrounding environment. These extrinsic influences vary across the lifespan and include cues from the local CNS environment, systemic immunity and the gut microbiome, as well as signals arising within the tumour microenvironment during glioma. Understanding how these intrinsic and extrinsic mechanisms spatiotemporally render different microglial activation states and functions has become a central challenge in the research of glioma biology, representing a promising avenue for therapeutic interventions.In line with these observations, this thesis investigates how intrinsic developmental programs and extrinsic cues shape microglia across the lifespan and influence the progression of glioma, one of the most aggressive brain tumours. In Paper I, we identified a distinct CD11c+ microglial activation state that promotes dysfunctional adaptive immune responses by chronically activating and exhausting the T cells in DMG. In Paper II, we investigated how DMG drives the remodelling of the gut microbiome which in turn is associated with the establishment of an immunosuppressive microglial niche within the tumour microenvironment. Considering bi-directional communication of the gut-brain-axis, in Paper III, we show that early-life microbiota shape developmental microglial programmes that influence susceptibility to DMG. In Paper IV, we identified the intrinsic ID2-ETS2 transcriptional axis that regulates a switch in microglia towards a pro-tumoral activation state in adult glioblastoma. Finally, in Paper V, we characterised age-associated microglial transcriptomic states that impair immunogenicity, providing insight into how ageing may contribute to the emergence and progression of adult gliomas. Collectively, these studies provide a framework for understanding how developmental, environmental and disease-associated factors shape microglial states and functions across the lifespan, offering new insights into their contribution to gliomagenesis and potential as therapeutic targets.List of scientific papersI. CD11c+ microglia promote dysfunctional T-cell activation in diffuse midline glioma. Austėja Balevičiūtė, Cristina Cuesta-Marti, Jessica Hincks, Mya McCarthy Hogan, Brendan L. Sharvin, Meghan McDermott, Jessica O'Reilly, Gabriel S.S. Tofani, Aimee du Chatinier, Gerard M. Moloney, Pat Fitzgerald, Cathriona Foley, Olivia F. O'Leary, Timothy N Phoenix, Esther Hullerman, Jon D. Larson, Suzanne J. Baker, Gerard Clarke, John F. Cryan & Lily Keane. Manuscript under revision at Immunity. [Submitted]II. Dynamic gut microbiome remodelling during diffuse midline glioma progression associates with an immunosuppressive microglial niche. Austėja Balevičiūtė*, Cristina Cuesta-Marti*, Ramya Balasubramanian*, Brendan L. Sharvin, Meghan McDermott, Jessica Hincks, Jessica O'Reilly, Aimee du Chatinier, Gerard M. Moloney, Pat Fitzgerald, Timothy N Phoenix, Esther Hullerman, Paul Cotter, Gerard...
- Open Access
- 21 June 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (7) , 804
Calcium Electrochemotherapy and Challenges in Combined Treatment with Dendritic Cell Vaccination
Background/Objectives: Electrochemotherapy (ECT) is a reliable and potent technique for managing primary tumors; however, significant efforts are being made to characterize and improve the systemic immune response, which is crucial for metastasis prevention. Current evidence suggests that the advancement of ECT will depend on its integration with complementary immunomodulatory methods. Methods: In this study, we examined the combined effects of calcium-based electrochemotherapy (CaECT, 1.3 kV/cm × 100 µs, eight pulses delivered at 1 Hz repetition frequency) with dendritic cell vaccination (DCV). Lewis lung carcinoma (LLC1) was used as a tumor model. We characterized the effects of CaECT alone and in combination with DCV therapy on tumor growth, analyzed the changes in immune cell subpopulations, and studied the humoral immune response dynamics on day 10, 20, and 30. Given the limited effect of DCV, additional experiments were conducted with the chemotherapeutic drug cyclophosphamide (CP), known for its immunomodulatory properties. Results: Although CaECT demonstrated potent antitumor activity and induced a significant immune response, its combination with DCV did not result in enhanced therapeutic efficacy. The combination of CP also failed to improve median survival. Conclusions: It is concluded that CaECT is a promising alternative to standard ECT involving bleomycin or cisplatin. However, further optimization is necessary to enhance the therapeutic synergy of CaECT when combined with DCV.
- 21 June 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (7) , 804
Open AccessCalcium Electrochemotherapy and Challenges in Combined Treatment with Dendritic Cell Vaccination
Background/Objectives: Electrochemotherapy (ECT) is a reliable and potent technique for managing primary tumors; however, significant efforts are being made to characterize and improve the systemic immune response, which is crucial for metastasis prevention. Current evidence suggests that the advancement of ECT will depend on its integration with complementary immunomodulatory methods. Methods: In this study, we examined the combined effects of calcium-based electrochemotherapy (CaECT, 1.3 kV/cm × 100 µs, eight pulses delivered at 1 Hz repetition frequency) with dendritic cell vaccination (DCV). Lewis lung carcinoma (LLC1) was used as a tumor model. We characterized the effects of CaECT alone and in combination with DCV therapy on tumor growth, analyzed the changes in immune cell subpopulations, and studied the humoral immune response dynamics on day 10, 20, and 30. Given the limited effect of DCV, additional experiments were conducted with the chemotherapeutic drug cyclophosphamide (CP), known for its immunomodulatory properties. Results: Although CaECT demonstrated potent antitumor activity and induced a significant immune response, its combination with DCV did not result in enhanced therapeutic efficacy. The combination of CP also failed to improve median survival. Conclusions: It is concluded that CaECT is a promising alternative to standard ECT involving bleomycin or cisplatin. However, further optimization is necessary to enhance the therapeutic synergy of CaECT when combined with DCV.
- 28 March 2025
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 25 (5) , 318
Macrophages promote nerve growth in both tumours and spinal cord
- 28 March 2025
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 25 (5) , 318
Macrophages promote nerve growth in both tumours and spinal cord
- Open Access
- 18 July 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (7) , 1-12
ID2-ETS2 axis regulates the transcriptional acquisition of pro-tumoral microglia phenotype in glioma
Glioblastoma is a highly aggressive brain tumour that creates an immunosuppressive microenvironment. Microglia, the brain’s resident immune cells, play a crucial role in this environment. Glioblastoma cells can reprogramme microglia to create a supportive niche that promotes tumour growth. However, the mechanisms controlling the acquisition of a transcriptome associated with a tumour-supportive microglial reactive state are not fully understood. In this study, we investigated changes in the transcriptional profile of BV2 microglia exposed to C6 glioma cells. RNA-sequencing analysis revealed a significant upregulation of microglial inhibitor of DNA binding 1 (Id1) and Id2, helix-loop-helix negative transcription regulatory factors. The concomitant regulation of microglial ETS proto-oncogene 2, transcription factor (ETS2)-target genes, i.e., Dusp6, Fli1, Jun, Hmox1, and Stab1, led us to hypothesize that ETS2 could be regulated by ID proteins. In fact, ID2-ETS2 protein interactions increased in microglia exposed to glioma cells. In addition, perturbation of the ID2-ETS2 transcriptional axis influenced the acquisition of a microglial tumour-supportive phenotype. ID2 and ETS2 genes were found to be expressed by the tumour-associated microglia isolated from human glioblastoma tumour biopsies. Furthermore, ID2 and ETS2 gene expressions exhibited inverse prognostic values in patients with glioma in cohorts from The Cancer Genome Atlas. Collectively, our findings indicate that the regulation of ETS2 by ID2 plays a role in the transcriptional regulation of microglia in response to stimuli originating from glioblastoma cells, information that could lead to developing therapeutic strategies to manipulate microglial tumour-trophic functions.
- 18 July 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (7) , 1-12
Open AccessID2-ETS2 axis regulates the transcriptional acquisition of pro-tumoral microglia phenotype in glioma
Glioblastoma is a highly aggressive brain tumour that creates an immunosuppressive microenvironment. Microglia, the brain’s resident immune cells, play a crucial role in this environment. Glioblastoma cells can reprogramme microglia to create a supportive niche that promotes tumour growth. However, the mechanisms controlling the acquisition of a transcriptome associated with a tumour-supportive microglial reactive state are not fully understood. In this study, we investigated changes in the transcriptional profile of BV2 microglia exposed to C6 glioma cells. RNA-sequencing analysis revealed a significant upregulation of microglial inhibitor of DNA binding 1 (Id1) and Id2, helix-loop-helix negative transcription regulatory factors. The concomitant regulation of microglial ETS proto-oncogene 2, transcription factor (ETS2)-target genes, i.e., Dusp6, Fli1, Jun, Hmox1, and Stab1, led us to hypothesize that ETS2 could be regulated by ID proteins. In fact, ID2-ETS2 protein interactions increased in microglia exposed to glioma cells. In addition, perturbation of the ID2-ETS2 transcriptional axis influenced the acquisition of a microglial tumour-supportive phenotype. ID2 and ETS2 genes were found to be expressed by the tumour-associated microglia isolated from human glioblastoma tumour biopsies. Furthermore, ID2 and ETS2 gene expressions exhibited inverse prognostic values in patients with glioma in cohorts from The Cancer Genome Atlas. Collectively, our findings indicate that the regulation of ETS2 by ID2 plays a role in the transcriptional regulation of microglia in response to stimuli originating from glioblastoma cells, information that could lead to developing therapeutic strategies to manipulate microglial tumour-trophic functions.
- 26 April 2024
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 24 (6) , 380
FAS signalling pathway is crucial for CAR T cell persistence
- 26 April 2024
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 24 (6) , 380
FAS signalling pathway is crucial for CAR T cell persistence
- Open Access
- 6 March 2024
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 24 (4) , 304
Author Correction: Clonal haematopoiesis-associated, age-related motor deficits caused by monocyte-derived microglia
- 6 March 2024
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 24 (4) , 304
Open AccessAuthor Correction: Clonal haematopoiesis-associated, age-related motor deficits caused by monocyte-derived microglia
- 30 January 2024
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 24 (3) , 160
Clonal haematopoiesis-associated, age-related motor deficits caused by monocyte-derived microglia
- 30 January 2024
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 24 (3) , 160
Clonal haematopoiesis-associated, age-related motor deficits caused by monocyte-derived microglia
- Open Access
- 29 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (87) , eadf7702
Laboratory mice with a wild microbiota generate strong allergic immune responses
Allergic disorders are caused by a combination of hereditary and environmental factors. The hygiene hypothesis postulates that early-life microbial exposures impede the development of subsequent allergic disease. Recently developed “wildling” mice are genetically identical to standard laboratory specific pathogen–free (SPF) mice but are housed under seminatural conditions and have rich microbial exposures from birth. Thus, by comparing conventional SPF mice with wildlings, we can uncouple the impact of lifelong microbial exposures from genetic factors on the allergic immune response. We found that wildlings developed larger populations of antigen-experienced T cells than conventional SPF mice, which included interleukin-10–producing CD4 T cells specific for commensal Lactobacilli strains and allergy-promoting T helper 2 (T H 2) cells. In models of airway exposure to house dust mite (HDM), recombinant interleukin-33, or Alternaria alternata , wildlings developed strong allergic inflammation, characterized by eosinophil recruitment, goblet cell metaplasia, and antigen-specific immunoglobulin G1 (IgG1) and IgE responses. Wildlings developed robust de novo T H 2 cell responses to incoming allergens, whereas preexisting T H 2 cells could also be recruited into the allergic immune response in a cytokine-driven and TCR-independent fashion. Thus, wildling mice, which experience diverse and lifelong microbial exposures, were not protected from developing pathological allergic immune responses. Instead, wildlings mounted robust allergic responses to incoming allergens, shedding new light on the hygiene hypothesis.
- 29 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (87) , eadf7702
Open AccessLaboratory mice with a wild microbiota generate strong allergic immune responses
Allergic disorders are caused by a combination of hereditary and environmental factors. The hygiene hypothesis postulates that early-life microbial exposures impede the development of subsequent allergic disease. Recently developed “wildling” mice are genetically identical to standard laboratory specific pathogen–free (SPF) mice but are housed under seminatural conditions and have rich microbial exposures from birth. Thus, by comparing conventional SPF mice with wildlings, we can uncouple the impact of lifelong microbial exposures from genetic factors on the allergic immune response. We found that wildlings developed larger populations of antigen-experienced T cells than conventional SPF mice, which included interleukin-10–producing CD4 T cells specific for commensal Lactobacilli strains and allergy-promoting T helper 2 (T H 2) cells. In models of airway exposure to house dust mite (HDM), recombinant interleukin-33, or Alternaria alternata , wildlings developed strong allergic inflammation, characterized by eosinophil recruitment, goblet cell metaplasia, and antigen-specific immunoglobulin G1 (IgG1) and IgE responses. Wildlings developed robust de novo T H 2 cell responses to incoming allergens, whereas preexisting T H 2 cells could also be recruited into the allergic immune response in a cytokine-driven and TCR-independent fashion. Thus, wildling mice, which experience diverse and lifelong microbial exposures, were not protected from developing pathological allergic immune responses. Instead, wildlings mounted robust allergic responses to incoming allergens, shedding new light on the hygiene hypothesis.
- Open Access
- 11 August 2023
- Published by MDPI AG in Veterinary Sciences
- Vol. 10 (8) , 519
Understanding the Immunomodulatory Effects of Bovine Colostrum: Insights into IL-6/IL-10 Axis-Mediated Inflammatory Control
Bovine colostrum (COL), the first milk secreted by lactating cows postpartum, is a rich source of bioactive compounds that exert a significant role in the survival, growth, and immune development of neonatal calves. This study investigated the immunomodulatory effects of COL on cytokine production in vitro using a Caco-2/THP-1 macrophage co-culture model stimulated with Phorbol 12-myristate 13-acetate (PMA). COL pretreatment significantly reduced IL-6 (241.3 pg/mL) production induced by PMA (p < 0.05), while increasing IL-10 production (45.3 pg/mL), in comparison to PMA control (441.1 and 12.5 pg/mL, respectively). Further investigations revealed that the IL-6 suppressive effect of colostrum was heat-sensitive and associated with components of higher molecular mass (100 kDa). Moreover, colostrum primarily influenced THP-1 macrophages rather than Caco-2 epithelial cells. The effects of colostrum on IL-6 production were associated with reduced NF-κB activation in THP-1 macrophages. In calf-FMT transplanted C57BL/6 murine model, colostrum decreased intestinal permeability, reduced immune cell infiltration and intestinal score, and suppressed IL-6 (142.0 pg/mL) production during S. typhimurium infection, in comparison to control animals (215.2 pg/mL). These results suggest the immunomodulatory activity of bovine colostrum and its potential applications in inflammatory disorders. Further studies are needed to elucidate the underlying mechanisms and validate the findings in bovine models.
- 11 August 2023
- Published by MDPI AG in Veterinary Sciences
- Vol. 10 (8) , 519
Open AccessUnderstanding the Immunomodulatory Effects of Bovine Colostrum: Insights into IL-6/IL-10 Axis-Mediated Inflammatory Control
Bovine colostrum (COL), the first milk secreted by lactating cows postpartum, is a rich source of bioactive compounds that exert a significant role in the survival, growth, and immune development of neonatal calves. This study investigated the immunomodulatory effects of COL on cytokine production in vitro using a Caco-2/THP-1 macrophage co-culture model stimulated with Phorbol 12-myristate 13-acetate (PMA). COL pretreatment significantly reduced IL-6 (241.3 pg/mL) production induced by PMA (p < 0.05), while increasing IL-10 production (45.3 pg/mL), in comparison to PMA control (441.1 and 12.5 pg/mL, respectively). Further investigations revealed that the IL-6 suppressive effect of colostrum was heat-sensitive and associated with components of higher molecular mass (100 kDa). Moreover, colostrum primarily influenced THP-1 macrophages rather than Caco-2 epithelial cells. The effects of colostrum on IL-6 production were associated with reduced NF-κB activation in THP-1 macrophages. In calf-FMT transplanted C57BL/6 murine model, colostrum decreased intestinal permeability, reduced immune cell infiltration and intestinal score, and suppressed IL-6 (142.0 pg/mL) production during S. typhimurium infection, in comparison to control animals (215.2 pg/mL). These results suggest the immunomodulatory activity of bovine colostrum and its potential applications in inflammatory disorders. Further studies are needed to elucidate the underlying mechanisms and validate the findings in bovine models.